Renal Denervation in Heart Failure Treatment: Data for a Self-Fulfilling Prophecy

Area of Science:

• Cardiovascular Medicine
• Nephrology
• Interventional Cardiology

Background:

• Hypertension and sympathetic overdrive are linked to heart failure (HF) development.
• Renal denervation (RDN) is a novel procedure for hypertension management.
• RDN's systemic effects suggest potential benefits for HF patients.

Purpose of the Study:

• To provide a rationale for using RDN in heart failure (HF) management.
• To review current data on RDN in HF patients with reduced and preserved ejection fraction.
• To discuss the future of neuromodulatory therapies in HF.

Main Methods:

• Review of existing studies on renal denervation in heart failure.
• Analysis of data concerning HF phenotypes (reduced and preserved ejection fraction).
• Exploration of RDN's impact on HF prognosis, symptoms, and adverse events.

Main Results:

• RDN is recognized as a third option for hypertension management in European guidelines.
• Early RDN research considered its use for overcoming diuretic resistance in HF.
• Investigational data explore RDN's potential to modify HF patient outcomes and symptoms.

Conclusions:

• Neuromodulation is increasingly significant in the HF therapeutic landscape.
• RDN offers a potential therapeutic avenue for HF patients.
• Further research is needed to establish RDN's role in HF management.